Samsung Bioepis will launch its biosimilar to Eylea, known as Opuviz (aflibercept-yszy), in the United States in January 2027, according to a company press release issued February 13, 2026.
Opuviz received approval from the Food and Drug Administration in 2024. The launch date follows a settlement and license agreement reached with Regeneron, the maker of the original Eylea (aflibercept), the release stated. Prior to the U.S. Launch, Opuviz became available in the United Kingdom in January 2026, with rollout across the rest of Europe planned for April 2026, and the rest of the world, excluding Korea, in May 2026.
Thomas Newcomer, vice president and head of U.S. Commercial operations at Samsung Bioepis, stated that aflibercept biosimilars, like Opuviz, “have the potential to significantly improve accessibility and affordability for patients.” He added that as demand for treatment grows, biosimilars can “help manage costs with confidence without compromising on clinical standards.”
The financial terms of the settlement between Samsung Bioepis and Regeneron remain confidential, the press release indicated.
